How Aduhelm, an Unproven Alzheimer’s Drug, Got Approved



Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.



Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top